Treatment outcome of tuberculosis patients diagnosed with human immunodeficiency virus infection in Iran
Abstract number: 1733_1114
Tabarsi P., Baghaei P., Amiri M., Emami H., Mansouri D., Masjedi M.
Background: Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) faces many problems due to pill burden, drug/drug interactions and toxicity. As there are yet no reports made on the treatment outcome of TB-HIV patients in Iran, this study aims to evaluate the outcome of treatment at the Masih Daneshvari Hospital, the National Referral Center for Tuberculosis and Lung Diseases in Tehran.
Methods: TB patients who were admitted to the hospital between the years 20022004 and tested positive for HIV were included in the study. 61 variables were chosen for comparison. All analysis was done using SPSS and significance was deduced via chi-square testing.
Results: 56 patients were included in the study. The mean CD4 count was 193 + 181 while the mean count at which death occurred was 128 + 41. Fifty percent of the cases were cured while mortality occurred in 15 cases (26.8%). The rate of mortality in patients who developed AIDS defining illnesses (ADI) was higher (35.1%). The most common adverse drug effect observed was hepatitis (14.3%). A Kaplan Meier of survival showed 50% of deaths occurring in the first four months of TB treatment. Comparison of patients who were receiving highly active antiretroviral therapy (HAART) and mortality did not yield significant results.
Conclusion: Even though the sample size of this study was limited, it can be suggested that mortality of TB/HIV patients is high. Starting HAART early for TB-HIV patients whose CD4 count is less than 130 can reduce the rate of mortality.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|